Description

Description Completed commissioning of commercial manufacturing facility；
CTA approved for DTcP and PBPV；
Completed phase Ⅲ clinical trials for MCV2 and MCV4；
Filed CTA for Pcv13i；

Description Co-Founder/Chief Executive Officer/Chairman

Description Chief Operating Officer/Executive Director

Description

Description CanSino Biologics Inc.

Description BEIJING — A team of Chinese health experts will depart for the Democratic Republic of Congo this week to help fight an Ebola outbreak in the west central African nation.

Description GENEVA (Reuters) - Democratic Republic of Congo's Ebola outbreak has been "largely contained" and no new cases of the disease have been confirmed since the last known sufferer died on June 9, the World Health Organization said on Wednesday.

Description Viral vector vaccine production technology is based on using a defective or extremely weak virus as a delivery vehicle for vaccines, introducing specific antigens into the human immune system to stimulate the formation of immune protection against specific diseases. Vaccines developed through this technology can rapidly stimulate the body to produce high levels of humoral immunity and generate strong cellular immunity. If administered through the mucosa, it can induce the body to produce a mucosal immune response. CanSinoBIO has established mature viral vector packaging technology, high cell density production process technology, and analytical characterization technology, enabling the rapid development of high-yield, quality-assured viral vector products using different cell substrates to meet various demands.

Description Polysaccharide vaccines are subunit vaccines for the prevention of infection against different bacterial pathogens, which are safe and efficacious. The technologies for the development and manufacturing of polysaccharide vaccines, which include polysaccharide antigen production, carrier protein production, polysaccharide-protein conjugation, as well as analytical techniques for intermediates and conjugates characterization and testing, have been well established in the company. We have also developed several carrier proteins which can be used to produce different glycoconjugate vaccines. The selection of appropriate carrier proteins and conjugation technologies is critical to reduce immune interference and ensure the immunogenicity of the vaccine. Our synthetic vaccine technology provides a technological foundation for the development of better multi-valent and combined vaccines.